 |
Stem and progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood |
|---|---|
| Trade Name | Stemex |
| Orphan Indication | For use as hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy |
| USA Market Approval | USA |
| USA Designation Date | 2005-03-04 00:00:00 |
| Sponsor | Gamida Cell Ltd - Teva Joint Venture;5, Nahum Hafzadi St., P. O. Box 34670;Jerusalem |
